Leading a renaissance in kidney disease treatment

Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease.

Year Invested: 2016
Location: Cambridge, Mass.
Visit: www.goldfinchbio.com

Recent News

July 18, 2017
ASHG Honors Daniel MacArthur with Inaugural Early-Career Award

February 9, 2017
Goldfinch Bio Appoints Nephrologist Louis Brenner, M.D., M.B.A. to Board of Directors

December 14, 2016
Third Rock Ventures launches Goldfinch Bio with $55M in Series A funding to bring precision medicine to patients with kidney disease

Read More News

Associated Team Members

Philip Reilly, M.D., J.D.
Venture Partner

Neil Exter

Abbie Celniker, Ph.D.